Adalimumab is a recombinant human IgG1 mAb targeting tumor necrosis factor-alpha (TNF-α) that has transformed the treatment of autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. Here, TNF is linked to rheumatoid arthritis.